Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_assertion description "[In order to define a useful TSP for targeting in the context of melanoma gene therapy, four promoters, the cyclooxygenase-2 (Cox-2), alpha-chemokine SDF-1 receptor (CXCR4), epithelial glycoprotein 2 (EGP-2), and survivin, were tested in both established melanoma cell lines and primary melanoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_assertion evidence source_evidence_literature NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_assertion SIO_000772 15696177 NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_assertion wasDerivedFrom befree-2016 NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_assertion wasGeneratedBy ECO_0000203 NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.
- befree-2016 importedOn "2016-02-19" NP479724.RA71Mo4rTj2h9BeHLvtVslQF2nmLY0bkCiN_-mWIflZpQ130_provenance.